Journal of Clinical Oncology, Vol 16, 2359-2363, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Ovarian function after autologous bone marrow transplantation

AD Schimmer, M Quatermain, K Imrie, V Ali, J McCrae, AK Stewart, M Crump, C Derzko and A Keating
University of Toronto Autologous Blood and Marrow Transplant Program and the Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada.

PURPOSE: To determine the frequency of return of ovarian function after autologous bone marrow transplantation (ABMT), and the major factors that predict recovery. PATIENTS AND METHODS: Records of 200 consecutive women who underwent ABMT at the University of Toronto Autologous Blood and Marrow Program (Toronto, Canada) were reviewed. Seventeen patients met the inclusion criteria, which were (1) alive at the time of evaluation, (2) disease-free at least 18 months after transplantation, (3) age younger than 50 years at transplantation, and (4) premenopausal before transplantation. Recovery of ovarian function was determined by pregnancy or regular menses, with no menopausal symptoms and an estradiol level greater than 20 pmol/L off hormonal therapy. RESULTS: All 17 patients became menopausal immediately after ABMT. Five patients (29%) recovered ovarian function a median of 24 months post-ABMT (range, 6 to 48 months). The median age at transplantation of women with restored ovarian function was 19 years (range, 19 to 28 years) versus 30 years (range, 22 to 48 years) for those who did not regain function. Younger age at transplantation predicted ovarian recovery (P = .03) by means of a log-rank test. Only one of five women who regained ovarian function received total-body irradiation (TBI) compared with five of 12 women who did not. Univariate analysis suggested a trend for TBI to predict a sustained loss of ovarian function (P = .067). The number of regimens of induction or salvage chemotherapy that contained an alkylating agent ranged from none to five and was not predictive (P = .45). CONCLUSION: All women became menopausal after ABMT but 29% recovered ovarian function. Younger age at transplantation predicted return of ovarian function, whereas TBI may have had a negative effect.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Oktay Spontaneous conceptions and live birth after heterotopic ovarian transplantation: is there a germline stem cell connection? Hum. Reprod., June 1, 2006; 21(6): 1345 - 1348. [Abstract] [Full Text] [PDF]

				C. S. Leger and T. J. Nevill Hematopoietic stem cell transplantation: a primer for the primary care physician Can. Med. Assoc. J., May 11, 2004; 170(10): 1569 - 1577. [Abstract] [Full Text] [PDF]

				L. Tauchmanova, C. Selleri, G. D. Rosa, M. Esposito, F. Orio Jr, S. Palomba, G. Bifulco, C. Nappi, G. Lombardi, B. Rotoli, et al. Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies Hum. Reprod., July 1, 2003; 18(7): 1410 - 1416. [Abstract] [Full Text] [PDF]

				P. Brice, C. Haioun, M. Andre, and C. Gisselbrecht Pregnancies after high-dose chemotherapy and autologous stem cell transplantation in aggressive lymphomas Blood, June 28, 2002; 100(2): 736 - 736. [Full Text] [PDF]